13F reference period
Q2 2026
Security Snapshot
BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT) Institutional Ownership
CUSIP: 107924102
13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026
Institutions Reporting
65
Shares (Excl. Options)
59.13M
Full value: 59,128,415 · shares · 30 Jun 2026Price
$7.62
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- BBOT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 59,128,415
- Total 13F value
- $450,584,191
- Portfolio coverage rank
- 0%
- Share change
- +1,592,894
- Value change
- +$8,267,743
- Number of holders
- 65
- Shares outstanding
- 80,101,228
- SEC-reported price per share
- $4.10
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- BBOT - BridgeBio Oncology Therapeutics, Inc. - Common Stock is tracked under CUSIP 107924102.
- 65 institutions reported positions in Q2 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 67 to 65 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$513.83M
Full value: $513,833,746 · USD · 31 Mar 2026.$450.58M
Full value: $450,584,191 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 65 institutions filings for Q2 2026.
Security key
107924102
13F reference period
Q2 2026
13F holders
65
13D/G owners
8
CIK / CUSIP context first
Open Q2 2026 holders
BBOT full holder history
BridgeBio Oncology Therapeutics, Inc. SEC filings
BridgeBio Oncology Therapeutics, Inc. company facts
BridgeBio Oncology Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 107924102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
8
Security
BBOT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Helix Holdings II LLC | 23% | 17,878,594 | Bihua Chen | 11 Aug 2025 | ||||
| Chen Bihua | 22% | $139,095,461 | 17,878,594 | Bihua Chen | 01 Jul 2026 | |||
| BridgeBio Pharma LLC | 18% | 13,878,554 | BridgeBio Pharma LLC | 11 Aug 2025 | ||||
| Flynn James E | 6.2% | 4,885,446 | Deerfield Management Company, L.P. | 11 Aug 2025 | ||||
| BC Global Opportunities IX LP | 5.5% | $42,740,663 | 4,365,747 | BC Global Opportunities IX LP | 04 Sep 2025 | |||
| CITADEL ADVISORS LLC | 3.2% | $29,391,684 | 2,538,142 | Kenneth Griffin | 30 Sep 2025 | |||
| Adage Capital Management, L.P. | 1.9% | $17,226,651 | 1,487,621 | Adage Capital Management, L.P. | 30 Sep 2025 | |||
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.1% | $10,248,786 | 885,042 | T. Rowe Price Associates, Inc. | 30 Sep 2025 |
As of 30 Jun 2026,
65
institutional investors reported holding
shares of
BridgeBio Oncology Therapeutics, Inc. - Common Stock (BBOT).
This represents
74%
of the company’s total
outstanding shares.
59.13M
Full value: 59,128,415 · shares · 30 Jun 202680.1M
Full value: 80,101,228 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
70%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 22% | 17,878,594 | 0% | 7% | $136,234,886 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 6.1% | 4,885,446 | 0% | 0.39% | $37,227,099 |
| Omega Fund Management, LLC | 4.1% | 3,289,661 | 0% | 13% | $25,067,217 |
| EcoR1 Capital, LLC | 3.5% | 2,823,126 | 0% | 1.1% | $21,512,220 |
| Alphabet Inc. | 3.5% | 2,823,126 | 0% | 0.02% | $21,512,220 |
| WELLINGTON MANAGEMENT GROUP LLP | 3.5% | 2,789,302 | -1% | 0% | $21,254,481 |
| ENAVATE SCIENCES GP, LLC | 3.3% | 2,626,946 | 0% | 5.8% | $20,017,329 |
| CITADEL ADVISORS LLC | 3.3% | 2,617,827 | +3.5% | 0.01% | $19,947,841 |
| NOVO HOLDINGS A/S | 2.8% | 2,250,000 | +2.9% | 1% | $17,145,000 |
| BlackRock, Inc. | 2.7% | 2,154,040 | +3.1% | 0% | $16,413,785 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 2,005,649 | +272% | 0% | $15,283,045 |
| Laurion Capital Management LP | 2.5% | 2,002,701 | +4.2% | 1.1% | $15,260,582 |
| ARMISTICE CAPITAL, LLC | 2.2% | 1,764,000 | +33% | 0.37% | $13,441,680 |
| STATE STREET CORP | 1.3% | 1,036,569 | +358% | 0% | $7,898,656 |
| Aisling Capital Management LP | 1.3% | 1,018,018 | 0% | 1.6% | $7,757,297 |
| Opaleye Management Inc. | 0.87% | 700,000 | +1214% | 0.48% | $5,334,000 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.78% | 622,351 | +7.4% | 0% | $4,744,649 |
| Granahan Investment Management, LLC | 0.7% | 558,526 | +142% | 0.15% | $4,255,968 |
| SPHERA FUNDS MANAGEMENT LTD. | 0.58% | 460,985 | 0.5% | $3,512,706 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.5% | 400,000 | 0% | 0% | $3,048,000 |
| ROYCE & ASSOCIATES LP | 0.48% | 384,941 | -40% | 0.02% | $2,933,250 |
| Catalio Capital Management, LP | 0.4% | 318,407 | 0.46% | $2,426,261 | |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.37% | 300,000 | -31% | 0% | $2,286,000 |
| VANGUARD FIDUCIARY TRUST CO | 0.36% | 291,522 | +15% | 0% | $2,221,398 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.36% | 286,518 | -1.5% | 0% | $2,183,267 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
5
Headline period
Q2 2026
Rows shown
1-5 of 5
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 2,665,829 | $10,927,020 | +$171,773 | $4.10 | 6 |
| 2026 Q2 | 59,128,415 | $450,584,191 | +$8,267,743 | $7.62 | 65 |
| 2026 Q1 | 57,435,188 | $513,833,746 | -$6,100,446 | $8.95 | 67 |
| 2025 Q4 | 57,897,060 | $724,704,890 | +$13,675,814 | $12.52 | 52 |
| 2025 Q3 | 56,812,363 | $657,547,712 | +$657,547,712 | $11.58 | 41 |